Mesenchymal stromal cells (MSC) represent a promising treatment option for tendon disorders and joint diseases, primarily osteoarthritis. Since MSC are highly context-sensitive to their microenvironment, their therapeutic efficacy is influenced by their tissue-specific pathologically altered targets. These include not only cellular components, such as resident cells and invading immunocompetent cells, but also components of the tissue-characteristic extracellular matrix. Although numerous in vitro models have already shown potential MSC-related mechanisms of action in tendon and joint diseases, only a limited number reflect the disease-specific microenvironment and allow conclusions about well-directed MSC-based therapies for injured tendon and joint-associated tissues. In both injured tissue types, inflammatory processes play a pivotal pathophysiological role. In this context, MSC-mediated macrophage modulation seems to be an important mode of action across these tissues. Additional target cells of MSC applied in tendon and joint disorders include tenocytes, synoviocytes as well as other invading and resident immune cells. It remains of critical importance whether the context-sensitive interplay between MSC and tissue- and disease-specific targets results in an overall promotion or inhibition of the desired therapeutic effects. This review presents the authors’ viewpoint on disease-related targets of MSC therapeutically applied in tendon and joint diseases, focusing on the equine patient as valid animal model.

Keywords: mesenchymal stromal cells (MSC), tendon, joint, osteoarthritis, context sensitivity, target, immunoregulation

INTRODUCTION

The former idea behind the application of mesenchymal stromal cells (MSC) in injured tissue was to transplant a source of undifferentiated progenitor cells and thereby achieve local effects, which were deemed to be a direct integration of MSC, further leading to restoration and regeneration at the site of injury. In musculoskeletal conditions, this is supported by studies investigating the retention and fate of locally applied MSC and by the repeated proof of MSC differentiation potential into osteogenic, chondrogenic, adipogenic and myogenic cell lines (Forest et al., 2010; Sole et al., 2013; Vieira et al., 2014). However, this assumption is more and more supplemented by findings about the ability of MSC to communicate transcellularly by direct cell-to-cell contact and release of soluble factors and extracellular vesicles (Islam et al., 2012; Liu et al., 2018; Witwer et al., 2019). With the knowledge of these transcellular communication mechanisms, the idea of a locally acting MSC requires a broader
**Possible Targets of MSC in Acute and Chronic Tendon Disease**

Possible targets of MSC in tendon disease include cellular components on the one hand, such as the resident tenocytes, invading immune cells and endothelial cells, and the extracellular matrix (ECM) on the other hand. Regeneration of the highly specialized matrix must always be the central goal, as it is responsible for tendon function. However, a functional replacement of cells and ECM by the MSC alone is unlikely to be achieved. Rather, the MSC should support a milieu which allows the tendon to regenerate. In this line, the cellular targets could be in the foreground in phases of active inflammation and acute injury, whereas the scarred ECM may need to be focused in chronic tendon disease.

In acute tendon disease or injury, activated tenocytes and invading immune cells, namely macrophages, foster a milieu of inflammation and further matrix degradation. Indeed, in a canine model of acute tendon injury, macrophages could be identified as a target of MSC treatment, which promoted their M1/M2 phenotype switch (Shen et al., 2016; Gelberman et al., 2017).

While the identification of the underlying molecular mechanisms and targets is more complex, this effect appeared to be mediated by interleukin (IL)-4 (Shen et al., 2016; Gelberman et al., 2017). The specific interplay of tenocytes and MSC in *vivo* has not been elucidated in much detail so far, yet besides direct tenocyte targeting, a protection of tenocytes *via* macrophage modulation and overall reduction of pro-inflammatory stimuli can be assumed (Manning et al., 2015). Furthermore, neovascularization plays a critical and often controversially discussed role in tendon healing, as it is crucial to successful healing but persistently increased vascularization negatively impacts long-term outcomes (Korntner et al., 2019; Liu et al., 2021). A transiently increased vascularization has repeatedly been observed as a response to MSC treatment of equine tendon lesions (Conze et al., 2014; Ahrberg et al., 2018). This suggests that vascular endothelial cells are targeted in a beneficial way, which likely is related to increased vascular endothelial growth factor (VEGF) levels (Okamoto et al., 2010; Yuksel et al., 2016).

In chronic tendon disease, failed ECM repair has led to scar tissue within the tendon. Its inferior biomechanical properties predispose to re-injury and its altered biophysical and biochemical properties fail to provide the appropriate guidance for regeneration to resident cells. Therefore, it appears advantageous to target the matrix remodeling process, with enzymatic degradation of scar matrix components and promotion of collagen I fibrillogenesis and cross-linking. So far, some insights into MSC-driven matrix remodeling *in vivo* can be deduced from studies dealing with acute equine tendon disease, but suitable models for chronic disease are lacking. Here, it could not only be shown that the tendon matrix has an improved architecture and composition after MSC injection (Schnabel et al., 2009; Crovace et al., 2010; Smith et al., 2013), but also that the treatment reduced collagenase [matrix metalloproteinase (MMP)13] activity (Smith et al., 2013) and upregulated stromelysin (MMP3) gene expression (Romero et al., 2017). This might indicate a selective and beneficial support of...
enzymatic tendon matrix remodeling, but data are still scarce and, importantly, these results were obtained after treatment of (sub)acute lesions but not after treatment of chronic disease.

**Possible Targets of MSC in Osteoarthritis**

Osteoarthritis (OA) was originally understood as a classical “wear and tear” disease, mainly related to degenerative changes in the articular cartilage. However, nowadays OA is referred to as a complex, multisystem disease affecting the whole joint and detailed pathophysiological mechanisms are still not completely understood. Nevertheless, it is beyond doubt that inflammatory processes in the synovial membrane play a crucial role in the initiation of OA and in promoting subsequent cartilage damage and pain at least in the inflammation-driven subset of patients (de Lange-Brokaar et al., 2012). Therefore, the previously suggested differentiation potential of MSC into chondrocytes aiding cartilage regeneration (Satué et al., 2019; Song et al., 2021) was pushed into the background against the ability of the MSC to target local immunocompetent cells.

OA-related synovitis is mainly driven by the innate immune system, which should therefore be targeted by MSC therapies, again with an outstanding role of macrophages. The macrophages potentially targeted by MSC include invading pro-inflammatory monocyte-derived macrophages within the synovial fluid and adjacent joint tissue as well as resident immunomodulatory synovial macrophages consisting of several subgroups of cells (van den Bosch, 2021). Besides their pivotal role in OA-related synovitis, synovial macrophages are considered critical for tissue homeostasis, thus being reasonably involved in the re-establishment of immune homeostasis within the injured joint. Recent studies in the mouse model indicate different roles of invading monocyte-derived and tissue resident synovial macrophages during homeostasis as well as disease. It was shown that locally renewing resident macrophages within the inner synovial lining form membrane-like structures as protective physical barrier between the intraarticular space and the synovial capillary network (Culemann et al., 2019). These resident synovial macrophages maintain their immune-regulatory function even within an inflammatory environment. However, the specific pathogenic role of these cells has not yet been addressed in OA (Haubruck et al., 2021). Tracking ferumoxytol-labeled murine MSC in a model of induced OA, MSC-treated joints were reported to show a reduced number of pro-inflammatory macrophages in favor of an increased proportion of homeostatic polarized macrophages (Hamilton et al., 2019). In co-culture models, it has been shown that MSC reduce M1-like-activating factors such as IL-1β and tumor necrosis factor (TNF)-α and induce typical M2-like macrophage markers such as IL-10, cluster of differentiation (CD)163 and CD206, partially through the prostaglandin E2/cyclooxygenase two pathway. Since this was shown in contact as well as in trans-well cultures, the authors suggest different MSC-mediated phases of immunomodulation including firstly an interaction via soluble factors and secondly a direct adhesion to the synovium (Manferdini et al., 2017). Yet so far, it remains to be understood whether applied MSC rather support tissue-resident macrophages or regulate primarily the inflammatory phenotype of the invading, mainly pro-inflammatory macrophages. In vivo and ex vivo models, ideally based on naturally occurring OA, could shed more light on these MSC-macrophage interactions.

Polymorphonuclear cells could represent a further target for MSC applied during OA-related synovitis. In a murine model of induced OA of the knee, locally applied MSC attracted colocalizing polymorphonuclear cells within the synovium. This was likely due to an IL-1β-mediated increased chemokine release of the applied MSC and led to the up-regulation of the phagocytic activity as well as the down-regulation of the pro-inflammatory cytokine release of the locally clustered polymorphonuclear cells (Van Dalen et al., 2019). This upregulation of the phagocytic activity might contribute to the removal of cartilage fragments from the synovial fluid, thus breaking the vicious inflammatory circle in OA.

**ADAPTION OF MSC TO THEIR TARGETS IN PATHOPHYSIOLOGICAL CONTEXTS**

MSCare highly sensitive to their environment, which entails a mutual interplay between the transplanted cells and their pathologically altered targets. The latter represent a crucial part of the disease milieu that will influence the MSC once transplanted (Table 1). It remains a central question whether their adaptation to the disease milieu leads to a promotion or inhibition of the desired effects on the respective targets.

Inflammatory conditions, which are often present in tendon as well as joint disease, are well-known to impact on MSC. MSC harvested from inflammatory environments show a decreased and variable fitness, which we have demonstrated for equine synovial fluid-derived MSC from osteoarthritic joints (Burk et al., 2017). In humans, the inflammatory state of synovial fluid in OA-affected knees modulates not only the proliferation of synovial fluid-derived MSC, but also induced a reduced differentiation potential, which is suggested to result in a lower ability to reverse OA (de Sousa et al., 2019). Additionally, MSC from discarded articular cartilage collected from OA patients during joint replacement therapy showed a rapid and strong mineralization upon chondrogenic induction, while markers of chondrocyte hypertrophy and stem cell osteogenesis were induced. These complex mechanisms demonstrate that MSC differentiation within the inflammatory environment might be coupled with undesired chondrocyte hypertrophy and osteogenesis (Hu et al., 2019).

Subjecting healthy MSC to inflammatory conditions impacts on their mode of action. This includes a decreased differentiation potential but can, up to a certain extent of inflammation, promote MSC immunomodulatory and protective mechanisms. With regard to tenogenic differentiation, we have shown that not only the presence of pro-inflammatory cytokines, namely IL-1β, but also the presence of leukocytes decreased the expression of the tendon transcription factor scleraxis in equine MSC (Brandt et al., 2018). Similarly, chondrogenic differentiation in pellet culture was decreased in the presence of the pro-inflammatory cytokines (Brandt et al., 2018), corresponding to findings in
TABLE 1 | Overview of microenvironmental factors and their effect on MSC potential mechanisms of action in tendon and joint disease.

| Microenvironmental factors influencing MSC mode of action in tendon and joint diseases | Cytokines, chemokines, enzymes, exosomes | Damaged resident cells, invading leukocytes | Extracellular matrix composition and architecture, oxygen tension |
|---|---|---|---|
| Soluble components | Cellular components | Extracellular environment |
| Differentiation potential ↓ | Immunomodulatory function ↑ | Angiogenic effects ↑ |
| • Reduced by inflammation | • Stimulated by hypoxia and inflammation | • Stimulated by hypoxia and inflammation |
| • Possible misrouted osteogenic differentiation | • Production of anti-/pro-inflammatory cytokines | • Growth factor release |
| • Regulatory effects on cells of the adaptive and innate immune system, including macrophages | | • Support of endothelial cells |
| Putative effects on therapeutically applied MSC in tendon and joint diseases | | Matrix remodeling ↓ |
| • Reduced by fibrotic extracellular matrix | • Altered matrix-degrading enzyme activity |

human MSC (Kondo et al., 2013; Liu et al., 2017). On the other hand, interestingly, chondrogenically differentiated equine MSC responded less to IL-1β stimulation than their naïve counterparts (Bundgaard et al., 2020). However, most likely more important than differentiation, pro-inflammatory stimulation has repeatedly been shown to increase MSC immunomodulatory potential. In a co-culture model using equine MSC and stimulated or non-stimulated leukocytes, we could show that the modulatory MSC mechanisms depended on the extent of inflammatory stimulation. Mild inflammatory conditions increased the percentage of MSC synthesizing the anti-inflammatory IL-10, while stronger inflammatory conditions promoted the regulatory effects of MSC on T cells, possibly via prostaglandin E2. However, not all effects observed in strong inflammatory conditions were strictly anti-inflammatory (Hillmann et al., 2019). With respect to joint disease, recent data has shown that synovial fluid collected from OA-affected joints influences the immunomodulatory properties of the MSC secretome and thereby promotes an anti-inflammatory subset of immune cells including an enhanced macrophage polarization into the M2-like phenotype (Cifù et al., 2020). Hypoxic conditions strongly influenced the migration and cytokine receptor expression of MSC cultured in synovial fluid collected from OA patients (Manferdini et al., 2020).

Extracellular matrices also have a strong impact on MSC properties and behavior (Li et al., 2021). However, the effects of pathologically altered ECM on MSC are still widely unknown, despite their relevance for treating chronic fibrotic conditions, attempting to specifically target the ECM. We observed that culturing equine MSC on decellularized tendon ECM failed to display synergistic effects with the tenogenic transforming growth factor (TGF)-β3 (Roth et al., 2018). This may be due to inhibitory effects of integrin/Rho/Rho-associated protein kinase (Rho/ROCK) axis activation by the extracellular matrix on canonical TGF-β3/smads signaling (Melzer et al., 2021), providing an example of cell-ECM interactions that could interfere with assumed mechanisms. Recently, we could also demonstrate that MSC undergo pathological adaptations upon exposure to scarred ECM. When culturing equine MSC on decellularized tendon matrices obtained from tendons with naturally occurred chronic disease, tenogenic differentiation was evident despite the ECM alterations in the tendon matrix, but the gene expression and activity of MMP was decreased (Doll et al., 2021). This effect was transient, but could hamper effective targeting of the scar tissue within the ECM.

DISCUSSION

Our growing understanding of pathophysiology and MSC behavior will promote the development of the next generation of MSC-based therapies. However, investigating target and therapeutic cells should go hand in hand and reflects naturally occurring disease. Deciphering the mutual interplay between MSC and their targets in relevant disease environments could provide the missing link for consistent therapeutic success. Recently, an interesting step in this direction was taken with the development of a bioassay, by which the effect of a patient’s OA joint microenvironment on the ability of MSC to support cartilage formation could be deduced. MSC-based cartilage formation was modified by the OA joint microenvironment, which could be useful to predict the therapeutic outcome (Neeffes et al., 2021). Such approaches may help to identify “non-responders” in advance and eventually lead to personalized OA treatments. Nevertheless, further strategies to deal with putative non-responders will still be required.

MSC priming, a promising strategy to enhance MSC potency and efficacy, directly results from the context-sensitive nature of the MSC, and aims to train the cells for their therapeutic task by subjecting them to pathophysiological stimuli. So far, this strategy has mainly been investigated with regard to inflammatory priming or “licensing” to enhance MSC immunomodulatory potential. For example, equine bone marrow-derived MSC primed with interferon (IFN)-γ were similarly activated as by co-culture with M1-polarized macrophages (Cassano et al., 2018). As the effects of IFN-γ were more consistent and also led to a chondroprotective secretome, the authors suggested that MSC priming before transplantation could be more successful than having the MSC activated by the pathological in vivo environment (Cassano et al., 2018), i.e., by their cellular targets, alone. In this line, in an equine model of chemically induced OA of the radio-carpal joint, inflammatory priming with TNF-α and IFN-γ led to an increased anti-inflammatory and regulatory effect of applied MSC. However, the repeated intraarticular application of inflammatory primed allogeneic MSC resulted in a slight transient inflammatory response,
possibly indicative for an increased immunogenicity of primed MSC (Barrachina et al., 2018). This must be carefully considered, along with the risk of exacerbation upon excessive stimulation, which might affect therapeutic safety of primed MSC. So far, a therapy with non-primed MSC, which naturally adapt to the disease environment, appears to be sufficient to target the immune cells in most patients and represents the safer option until more knowledge is available. However, MSC priming may help non-responding patients and this concept in general appears highly valuable for future therapies.

Aiming to further improve MSC priming approaches, it will be interesting whether priming regimes can be tailored for specific targeting of certain cell types or ECM components. With respect to tendon and OA therapies, macrophages remain the most promising cell type to modulate or alter their functional phenotype, as key regulatory cells in tendon as well as OA-related inflammation. However, little is known about the conditions of the disease environment in which MSC target inflammation and decrease the pro-inflammatory state of macrophages at their best (van den Bosch, 2021). Therefore, pre-treatment options to improve MSC efficacy by targeted influencing of tendon and joint-associated macrophages should be set on the scientific agenda. This implies optimizing MSC and target macrophage communication applicable for different disease stages, including conditions with an unfavourable environment such as the exacerbated OA-related synovitis.

We conclude that the mode of action of locally applied MSC is influenced by the cellular and molecular microenvironment at the injured site and vice versa. In this context, MSC-mediated macrophage modulation represents a key tool to positively influence inflammation in injured tendons and joints. However, a broad range of additional target cells as well as the ECM also have to be addressed. The best possible outcome for any MSC recipient will be achieved when the target tissue is characterized and the applied MSC, including potential priming, are matched with each other as specifically as possible.

DATA AVAILABILITY STATEMENT

The original contributions presented in the study are included in the article/Supplementary Material, further inquiries can be directed to the corresponding author.

AUTHOR CONTRIBUTIONS

AT, JB, and SR constructed the manuscript. AT, JB, SR, and WB edited the manuscript. All authors contributed to the article and approved the submitted version.

FUNDING

This work was partially funded by the a grant from the Leipzig veterinary junior scientist support program financed by the “Freundeskreis Tiermedizin” and the Faculty of Veterinary Medicine, University of Leipzig.

REFERENCES

Ackerman, J. E., Best, K. T., Muscat, S. N., and Loiselle, A. E. (2021). Metabolic Regulation of Tendon Inflammation and Healing Following Injury. Curr. Rheumatol. Rep. 23, 15. doi:10.1007/s11926-021-00981-4

Ahrberg, A. B., Horstmeier, C., Berner, D., Brehm, W., Gittel, C., Hillmann, A., et al. (2018). Effects of Mesenchymal Stromal Cells versus Serum on Tendon Healing in a Controlled Experimental Trial in an Equine Model. BMC Musculoskelet. Disord. 19, 1–14. doi:10.1186/s12891-018-2163-y

Barrachina, L., Remacha, A. R., Romero, A., Vitoria, A., Albareda, J., Prades, M., et al. (2018). Assessment of Effectiveness and Safety of Repeat Administration of Proinflammatory Primed Allogeneic Mesenchymal Stem Cells in an Equine Model of Chemically Induced Osteoarthritis. BMC Vet. Res. 14, 1–17. doi:10.1186/s12917-018-1556-3

Becerra, P., Valdés Vázquez, M. A., Duddhia, J., Fiske-Jackson, A. R., Neves, F., Hartman, N. G., et al. (2013). Distribution of Injected Technetium99m-labeled Mesenchymal Stem Cells in Horses with Naturally Occurring Tendinopathy. J. Orthop. Res. 31, 1096–1102. doi:10.1002/jor.22338

Berner, D., Brehm, W., Gerlach, K., Gittel, C., Offhaus, J., Paebst, F., et al. (2016). Longitudinal Cell Tracking and Simultaneous Monitoring of Tissue Regeneration after Cell Treatment of Natural Tendon Disease by Low-Field Magnetic Resonance Imaging. Stem Cell Int. 2016, 1–13. doi:10.1155/2016/1207190

Brandt, L., Schubert, S., Scheibe, P., Brehm, W., Franzen, J., Gross, C., et al. (2018). Tenogenic Properties of Mesenchymal Progenitor Cells Are Compromised in an Inflammatory Environment. Jims 19, 2549–2626. doi:10.3390/jims19092549

Brecht, S. S., Soy, B., Suls, M., Vandenberghhe, A., Mariën, T., Adriaensen, E., et al. (2019). Equine Allogeneic Chondrogenic Induced Mesenchymal Stem Cells Are an Effective Treatment for Degenerative Joint Disease in Horses. Stem Cell Dev. 28, 410–422. doi:10.1089/scd.2018.0061

Crovace, A., Lacitignola, L., Rossi, G., and Francioso, E. (2010). Histological and Immunohistochemical Evaluation of Autologous Cultured Bone Marrow Mesenchymal Stem Cells and Bone Marrow Mononucleated Cells in Collagenase-Induced Tendinitis of Equine Superficial Digital Flexor Tendon. Vet. Med. Int. 2010, 1–10. doi:10.4061/2010/259978

Roth et al. MSC in Tendon and Joint Disease

Frontiers in Bioengineering and Biotechnology | www.frontiersin.org 5 April 2022 | Volume 10 | Article 855095
Khan, M. R., Smith, R. K., David, F., Lam, R., Hughes, G., Godoy, R., et al. (2020). Osteoarthritis and Cartilage 20, 1484–1499. doi:10.1016/j.joca.2020.10.007

de Sousa, E. B., dos Santos Junior, G. C., Aguiar, R. P., da Costa Sartore, R., de Oliveira, A. C. L., Almeida, F. C. L., et al. (2019). Osteoarthritis and Synovial Fluid Modulates Cells Phenotype and Metabolic Behavior In Vitro. Stem Cell Int. 2019, 1–14. doi:10.1186/s12955-019-1861-2

Delling, U., Brehm, W., Ludewig, E., Winter, K., and Jülke, H. (2015). Longitudinal Evaluation of Effects of Intra-articular Mesenchymal Stromal Cell Administration for the Treatment of Osteoarthritis in an Ovine Model. Cell Transpl. 24, 2391–2407. doi:10.3727/0969815X686193

Doll, C. U., Niebert, S., and Burk, J. (2021). Mesenchymal Stromal Cells Adapt to Chronic Tendon Disease Environment with an Initial Reduction in Matrix Remodeling. Jmm. 22, 12798. doi:10.3390/jmm222312798

Forest, V. F., Tirouvanziam, A. M., Perigaud, C., Fernandes, S., Fusellier, M. S., Hillmann, A., Paebst, F., Brehm, W., Piehler, D., Schubert, S., Tárnok, A., et al. (2018). Intra-articular Mesenchymal Stem Cell Administration for the Treatment of Osteoarthritis in a Large Animal Model of Intra-Synovial Tendinopathy. Front. Physiol. 9, 1281. doi:10.3389/fphys.2018.01281

J. Orthop. Res. 27, 1161–1171. doi:10.1002/jor.24096

Manning, C. N., Martel, C., Sakiyama-Elbert, S. E., Silva, M. J., Shah, S., Gelberman, R. H., et al. (2015). Adipose-derived Mesenchymal Stromal Cells Modulate Tendon Fibroblast Responses to Macrophage Induced Inflammation In Vitro. Stem Cell Res. Ther. 6, 1–14. doi:10.1186/s13287-015-0059-4

Melzer, M., Schubert, S., Müller, S. F., Geyer, J., Hagen, A., Niebert, S., et al. (2021). Rho/ROCK Inhibition Promotes TGFB-3-Induced Tenogenic Differentiation in Mesenchymal Stromal Cells. Stem Cell Int. 2021, 1–11. doi:10.1155/2021/8284690

Neeffes, M., Houmans, B. C. A. M., van Beuning, H. M., Vitters, E. L., van den Akker, G. G. H., van den Akker, G. G. H., et al. (2021). Prediction of the Effect of the Osteoarthritic Joint Microenvironment on Cartilage Repair. Tissue Eng. Part A. 27, 16. doi:10.1089/tea.2021.0051

Okamoto, N., Kushida, T., Imai, M., Nakamura, K., Iida, H. (2010). Treating Rotator Cuff Tendon Tear Using Umbilical Cord Blood-Derived Mesenchymal Stem Cells. Arthritis Res. Ther. 12, 1–14. doi:10.1186/s13075-019-0155-6

Satué, M., Schüler, C., Ginner, N., and Erben, R. G. (2019). Intra-articularly Injected Mesenchymal Stem Cells Promote Cartilage Regeneration, but Do Not Permanently Engraft in Distant Organs. Sci. Rep. 9, 1–10. doi:10.1038/s41598-019-46554-5

Sanchello, C., and Goldring, S. R. (2021). The Role of Synovitis in Osteoarthritis Pathogenesis. Bone 51, 249–257. doi:10.1016/j.bone.2012.02.012

Schubert, S. E., Lynch, M. E., van der Meulen, M. C. H., Yeager, A. E., Kornatowski, M. A., and Nixon, A. J. (2009). Mesenchymal Stem Cells and Insulin-like Growth Factor-I Gene-Enhanced Mesenchymal Stem Cells Improve Structural Aspects of Healing in Equine Flexor Digitorum Superficialis Tendons. J. Orthop. Res. 27, 1347–13450. doi:10.1007/s10992-009-9792-0

Satu, M., Schier, C., Ginner, N., and Erben, R. G. (2019). Intra-articularly Injected Mesenchymal Stem Cells Promote Cartilage Regeneration, but Do Not Permanently Engraft in Distant Organs. Sci. Rep. 9, 1–10. doi:10.1038/s41598-019-46554-5

Sanchello, C., and Goldring, S. R. (2021). The Role of Synovitis in Osteoarthritis Pathogenesis. Bone 51, 249–257. doi:10.1016/j.bone.2012.02.012

Schubert, S. E., Lynch, M. E., van der Meulen, M. C. H., Yeager, A. E., Kornatowski, M. A., and Nixon, A. J. (2009). Mesenchymal Stem Cells and Insulin-like Growth Factor-I Gene-Enhanced Mesenchymal Stem Cells Improve Structural Aspects of Healing in Equine Flexor Digitorum Superficialis Tendons. J. Orthop. Res. 27, 1347–13450. doi:10.1007/s10992-009-9792-0

Shen, H., Kornpmak, I., Havelrou, N., Linderman, S. W., Sakiyama-Elbert, S. E., Erickson, I. E., et al. (2016). The Effect of Mesenchymal Stromal Cell Sheets on the Inflammatory Stage of Flexor Tendon Healing. Stem Cell Res. Ther. 7, 1–13. doi:10.1186/s13287-016-0406-0

Smith, R. R., Welting, N. J., Dukin, S. G., Alam, R., Goodship, A. E., and Dudia, J. (2013). Beneficial Effects of Autologous Bone Marrow-Derived Mesenchymal Stem Cells in Naturally Occurring Tendinopathy. PLoS One 8, e56970. doi:10.1371/journal.pone.005697

Sole, A., Spriet, M., Pagedt, K. A., Vaughan, B., Galuppo, L. D., Borjeson, D. L., et al. (2013). Distribution and Persistence of Technetium-99 Hexamethyl Propylene Amine Oxime-Labelled Bone Marrow-Derived Mesenchymal Stem Cells in Experimentally Induced Tendon Lesions after Intratendinous
Injection and Regional Perfusion of the Equine Distal Limb. *Equine Vet. J.* 45, 726–731. doi:10.1111/evj.12063

Song, H., Zhao, J., Cheng, J., Feng, Z., Wang, J., Momtazi-Borojeni, A. A., et al. (2021). Extracellular Vesicles in Chondrogenesis and Cartilage Regeneration. *J. Cel. Mol. Med.* 25, 4883–4892. doi:10.1111/jcmm.16290

Van Dalen, S. C. M., Blom, A. B., Walgreen, B., Sloetjes, A. W., Helsen, M. M. A., Geven, E. J. W., et al. (2019). IL-1β-mediated Activation of Adipose-Derived Mesenchymal Stromal Cells Results in PMN Reallocation and Enhanced Phagocytosis: A Possible Mechanism for the Reduction of Osteoarthritis Pathology. *Front. Immunol.* 10, 1–13. doi:10.3389/fimmu.2019.01075

van den Bosch, M. H. J. (2021). Osteoarthritis Year in Review 2020: Biology. *Osteoarthr. Cartil.* 29, 143–150. doi:10.1016/j.joca.2020.10.006

Vieira, M., Oliveira, R. J., Eça, L., Pereira, I., Hermeto, L. C., Matuo, R., et al. (2014). Therapeutic Potential of Mesenchymal Stem Cells to Treat Achilles Tendon Injuries. *Genet. Mol. Res.* 13, 10434–10449. doi:10.4238/2014.Dece.12.5

Witwer, K. W., Van Balkom, B. W. M., Bruno, S., Choo, A., Dominici, M., Gimona, M., et al. (2019). Defining Mesenchymal Stromal Cell (MSC)-derived Small Extracellular Vesicles for Therapeutic Applications. *J. Extracell. Vesicles* 8, 1609206. doi:10.1080/20013078.2019.1609206

Yuksel, S., Guleç, M. A., Gultekin, M. Z., Adanur, O., Caglar, A., Beytemur, O., et al. (2016). Comparison of the Early Period Effects of Bone Marrow-Derived Mesenchymal Stem Cells and Platelet-Rich Plasma on the Achilles Tendon Ruptures in Rats. *Connect. Tissue Res.* 57, 360–373. doi:10.1080/03008207.2016.1189909

**Conflict of Interest:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

**Publisher’s Note:** All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2022 Roth, Burk, Brehm and Troillet. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.